NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » Schering-Plough back to previous page show list

Schering-Plough

»
address: 2000 Galloping Hill Road,
Kenilworth,
N.J. 07033-0530
contact: Tel: (908) 298-4000
key person: Fred Hassan
Chairman of the Board and Chief Executive Officer

Robert J. Bertolini
Executive Vice President and Chief Financial Officer

C. Ron Cheeley
Senior Vice President, Global Human Resources

trunover in millions USD: 10600
R & D turnover in millions USD: 2200
NET profit: 1100
year of financial results: 2006
employees: 33500

active in China: YES
partner in China: Schering-Plough (China) Ltd.
Shanghai Schering-Plough Pharmaceutical Co., Ltd.

25/F Hai Tong Securities Tower,
No. 689 Guangdong Road,
Shanghai 200001
China

SFDA approved: YES
SFDA approved date: 10/08/2005
Address & Contact Details: Telephone: +86 21 6431 1100
Fax: +86 21 6431 1112
key personnel: Trevor Juniper ,General Manager, of Schering-Plough China

Approvals:
GLP: NO
GMP: YES
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: YES
Active Pharmaceutical: NO
R&D: NO
Ingredients: NO
Western Generics: NO
TCM: NO

R & D:
Discovery: NO
Work Up (pilot to production): NO
Analysis: NO
Quality Control: NO
Stability: NO
Batch Release: NO

Clinical trials:
Run/Manage: NO
Data management: NO
Support Labs: NO

Non clinical & preclinical:
Animal Testing: GLP: NO
New materials Safety Assessment: NO
Pharmaceuticals: NO
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
API: NO
Licensed Drugs: NO

test:
R&D: NO
 

First established in the late 1800s as the U.S. subsidiary of Schering AG, a German-based pharmaceutical and chemical company, Schering Corporation was incorporated in New York City in 1928, and in New Jersey in 1935. Schering Corporation's first offering consisted of a modest but promising line of pharmaceutical products to U.S. consumers, which led to steady growth and a rapid expansion of facilities.

The 1940s proved to be a key decade in the history of the company, as it evolved from a European-based company with U.S. operations into a truly American enterprise. Schering Corporation had been nationalized by the U.S. government during World Wars I and II, and in 1952 the company passed into the private sector.

For Schering, the 1950s and 1960s were characterized by continued growth, attributable to research and development and acquisition activities. Schering Corporation grew to become a global research-based pharmaceutical firm, and in 1971, merged with Plough Inc., a worldwide manufacturer of consumer products, to create Schering-Plough Corporation. The merger proved successful, as only a decade later the company's sales had grown fourfold.

During the 1980s and 1990s, Schering-Plough refined its focus on four key therapeutic areas and continued to excel at innovative approaches to treating disease. New research technologies acquired during this time quickly became important tools in Schering-Plough's research program, enabling the company to achieve important pharmaceutical advances and significant breakthroughs in antihistamines, corticosteroids, antibiotics, anti-infectives and antiviral products. Over the years, Schering-Plough also has divested and acquired businesses and entered into alliances to strengthen its worldwide competitiveness.

In April 2003, Fred Hassan joined Schering-Plough as chief executive officer and was elected chairman by the Board of Directors. Under his direction, Schering-Plough is embarking on an overall turnaround strategy for the organization. By focusing on the basics, earning the trust of all stakeholders and developing innovative products with the potential to improve people's health and extend lives, Schering-Plough is undergoing transformational change in order to achieve success in today's competitive environment.

Schering-Plough in China

Shanghai Schering-Plough Pharmaceutical Co., Ltd. was set up in 1994.

The total investment is 37 USD million.
  • China Schering-Plough (China) Ltd.
  • Shanghai Schering-Plough Pharmaceutical Co., Ltd.


AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.